Two Distinct Gamma Interferon-Inducible Promoters of the Major Histocompatibility Complex Class II Transactivator Gene Are Differentially Regulated by STAT1, Interferon Regulatory Factor 1, and Transforming Growth Factor β

REFERENCES

• Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72:248–254.
   PubMed Web of Science ®Google Scholar
• Brasier, A. R., J. E. Tate, and J. Habener 1989. Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. BioTechniques 7:1116–1122.
   PubMed Web of Science ®Google Scholar
• Chang, C.-H., S. Guerder, S.-C. Hong, W. van Ewijk, and J. Flavell 1996. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4:167–178.
   PubMed Web of Science ®Google Scholar
• Chang, C. H., J. D. Fontes, M. Peterlin, and J. Flavell 1994. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. Med. 180:1367–1374.
   PubMedGoogle Scholar
• Chin, K.-C., G. X. Li, and J. Ting 1997. Importance of acidic, proline/serine/threonine-rich, and GTP-binding regions in the major histocompatibility complex class II transactivator: generation of transdominant-negative mutants. Proc. Natl. Acad. Sci. USA 94:2501–2506.
   PubMedGoogle Scholar
• Chin, K.-C., C. Mao, C. Skinner, J. L. Riley, K. L. Wright, C. S. Moreno, G. R. Stark, J. M. Boss, and J. Ting 1994. Molecular analysis of G1B and G3A IFN-γ mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity 1:687–697.
   PubMedGoogle Scholar
• Cressman, D. E., K.-C. Chin, D. J. Taxman, and J.P.-Y. Ting. Submitted for publication.
   Google Scholar
• Darnell, J. E. Jr.. 1997. STATs and gene regulation. Science 277:1630–1635.
   PubMed Web of Science ®Google Scholar
• Denzin, L. K., and J. Cresswell 1995. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 82:155–165.
   PubMed Web of Science ®Google Scholar
• Fling, S. P., B. Arp, and J. Pious 1994. HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 368:554–558.
   PubMed Web of Science ®Google Scholar
• Fontes, J. D., N. Jabrane-Ferrat, C. R. Toth, and J. Peterlin 1996. Binding and cooperative interactions between two B cell-specific transcriptional coactivators. J. Exp. Med. 183:2517–2521.
   PubMedGoogle Scholar
• Fontes, J. D., B. Jiang, and J. Peterlin 1997. The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res. 25:2522–2528.
   PubMed Web of Science ®Google Scholar
• Fremont, D. H., W. A. Hendrickson, P. Marrack, and J. Kappler 1996. Structures of an MHC class II molecule with covalently bound single peptides. Science 272:1001–1004.
   PubMed Web of Science ®Google Scholar
• Geiser, A. G., J. J. Letterio, A. B. Kulkarni, S. Karlsson, A. B. Roberts, and J. Sporn 1993. Transforming growth factor beta 1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc. Natl. Acad. Sci. USA 90:9944–9948.
   PubMed Web of Science ®Google Scholar
• Ghosh, P., M. Amaya, E. Mellins, and J. Wiley 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378:457–462.
   PubMed Web of Science ®Google Scholar
• Glimcher, L. H., and J. Kara 1992. Sequences and factors: a guide to MHC class-II transcription. Annu. Rev. Immunol. 10:13–49.
   PubMed Web of Science ®Google Scholar
• Harton, J. Personal communication.
   Google Scholar
• Hobart, M., V. Ramassar, N. Goes, J. Urmson, and J. Halloran 1997. IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. J. Immunol. 158:4260–4269.
   PubMed Web of Science ®Google Scholar
• Improta, T., C. Schindler, C. M. Horvath, I. M. Kerr, G. R. Stark, J. E. Darnell Jr.. 1994. Transcription factor ISGF-3 formation requires phosphorylated Stat91 protein, but Stat113 protein is phosphorylated independently of Stat91 protein. Proc. Natl. Acad. Sci. USA 91:4776–4780.
   PubMedGoogle Scholar
• Itoh-Lindstrom, Y., J. F. Piskurich, Y. Wang, J. Platt, B. H. Koller, and J.P.-Y. Ting. Submitted for publication.
   Google Scholar
• Kerr, L. D., D. B. Miller, and J. Matrisian 1990. TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell 61:267–278.
   PubMed Web of Science ®Google Scholar
• Kretzschmar, M., and J. Massague 1998. SMADs: mediators and regulators of TGF-β signaling. Curr. Opin. Genet. Dev. 8:103–111.
   PubMed Web of Science ®Google Scholar
• Labbe, E., C. Silvestri, P. A. Hoodless, J. L. Wrana, and J. Attisano 1998. Smad2 and Smad3 positively and negatively regulate TGFβ-dependent transcription through the forkhead DNA-binding protein FAST2. Mol. Cell 2:109–120.
   PubMed Web of Science ®Google Scholar
• Lee, Y. J., Y. Han, H. T. Lu, V. Nguyen, H. Qin, P. H. Howe, B. A. Hocevar, J. M. Boss, R. M. Ransohoff, and J. Benveniste 1997. TGF-β suppresses IFN-γ induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J. Immunol. 158:2065–2075.
   PubMed Web of Science ®Google Scholar
• Lennon, A. M., C. Ottone, G. Rigaud, L. L. Deaven, J. Longmire, M. Fellous, R. Bono, and J. Alcaide-Loridan 1997. Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics 45:266–273.
   PubMedGoogle Scholar
• Letterio, J. J., A. G. Geiser, A. B. Kulkarni, H. Dang, L. Kong, T. Nakabayashi, C. L. Mackall, R. E. Gress, and J. Roberts 1996. Autoimmunity associated with TGF-β1-deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Investig. 98:2109–2119.
   PubMed Web of Science ®Google Scholar
• Loh, J. E., C. H. Chang, W. L. Fodor, and J. Flavell 1992. Dissection of the interferon gamma-MHC class II signal transduction pathway reveals that type I and type II interferon systems share common signaling component(s). EMBO J. 11:1351–1363.
   PubMed Web of Science ®Google Scholar
• Mach, B., V. Steimle, E. Martinez-Soria, and J. Reith 1996. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14:301–331.
   PubMed Web of Science ®Google Scholar
• Mahanta, S. K., T. Scholl, F. C. Yang, and J. Strominger 1997. Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc. Natl. Acad. Sci. USA 94:6324–6329.
   PubMedGoogle Scholar
• Mao, C., D. Davies, I. M. Kerr, and J. Stark 1993. Mutant human cells defective in induction of major histocompatibility complex class II genes by interferon gamma. Proc. Natl. Acad. Sci. USA 90:2880–2884.
   PubMedGoogle Scholar
• Martin, W. D., G. G. Hicks, S. K. Mendiratta, H. I. Leva, H. E. Ruley, and J. Van Kaer 1996. H2-mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 84:543–550.
   PubMedGoogle Scholar
• Meraz, M. A., J. M. White, K. C. F. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, K. Carver-Moore, R. N. DuBois, R. Clark, M. Aguet, and J. Schreiber 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431–442.
   PubMed Web of Science ®Google Scholar
• Miyazaki, T., P. Wolf, S. Tourne, C. Waltzinger, A. Dierich, N. Barois, H. Ploegh, C. Benoist, and J. Mathis 1996. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 84:531–541.
   PubMedGoogle Scholar
• Muhlethaler-Mottet, A., W. Di Berardino, L. A. Otten, and J. Mach 1998. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8:157–166.
   PubMed Web of Science ®Google Scholar
• Muhlethaler-Mottet, A., L. A. Otten, V. Steimle, and J. Mach 1997. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16:2851–2860.
   PubMed Web of Science ®Google Scholar
• Nakabayashi, T., J. J. Letterio, A. G. Geiser, L. Kong, N. Ogawa, W. Zhao, T. Koike, G. Fernandes, H. Dang, and J. Talal 1997. Up-regulation of cytokine mRNA, adhesion molecule proteins, and MHC class II proteins in salivary glands of TGF-β1 knockout mice: MHC class II is a factor in the pathogenesis of TGF-β1 knockout mice. J. Immunol. 158:5527–5535.
   PubMed Web of Science ®Google Scholar
• Nandan, D., and J. Reiner 1997. TGF-β attenuates the class II transactivator and reveals an accessory pathway of IFN-γ action. J. Immunol. 158:1095–1101.
   PubMed Web of Science ®Google Scholar
• Nguyen, H., J. Hiscott, and J. Pitha 1997. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 8:293–312.
   PubMedGoogle Scholar
• Pellegrini, S., J. John, M. Shearer, I. M. Kerr, and J. Stark 1989. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol. Cell. Biol. 9:4605–4612.
   PubMedGoogle Scholar
• Pfeifer, G. P., R. L. Tanguay, S. D. Steigerwald, and J. Riggs 1990. In vivo footprint and methylation analysis by PCR-aided genomic sequencing: comparison of active and inactive X chromosome DNA at the CpG island and promoter of human PGK-1. Genes Dev. 4:1277–1287.
   PubMed Web of Science ®Google Scholar
• Piskurich, J. F., Y. Wang, M. W. Linhoff, L. C. White, and J. Ting 1998. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-γ, STAT1, and TGF-β-regulated expression of the class II transactivator gene. J. Immunol. 160:233–240.
   PubMedGoogle Scholar
• Piskurich, J. F. Unpublished data.
   Google Scholar
• Rein, T., M. Muller, and J. Zorbas 1994. In vivo footprinting of the IRF-1 promoter: inducible occupation of a GAS element next to a persistent structural alteration of the DNA. Nucleic Acids Res. 22:3033–3037.
   PubMedGoogle Scholar
• Rigaud, G., A. D. Barbaro, M. Nicolis, T. Cestari, D. Ramarli, A.-P. Riviera, and J. Accolla 1996. Induction of CIITA and modification of in vivo HLA-DRA promoter occupancy in normal thymic epithelial cells treated with IFN-γ. J. Immunol. 156:4254–4258.
   PubMed Web of Science ®Google Scholar
• Sambrook, J., E. F. Fritsch, T. Maniatis 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
   Google Scholar
• Scholl, T., S. K. Mahanta, and J. Strominger 1997. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc. Natl. Acad. Sci. USA 94:6330–6334.
   PubMedGoogle Scholar
• Schreiber, E., P. Matthias, M. M. Muller, and J. Schaffner 1989. Rapid detection of octamer binding proteins with ‘mini-extracts’, prepared from a small number of cells. Nucleic Acids Res. 17:6419.
   PubMed Web of Science ®Google Scholar
• Sherman, M. A., D. A. Weber, and J. Jensen 1995. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity 3:197–205.
   PubMed Web of Science ®Google Scholar
• Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, and J. Calvin 1992. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359:693–699.
   PubMed Web of Science ®Google Scholar
• Sims, T. N., N. B. Goes, V. Ramassar, J. Urmson, and J. Halloran 1997. In vivo class II transactivator expression in mice is induced by a non-interferon-gamma mechanism in response to local injury. Transplantation 64:1657–1664.
   PubMedGoogle Scholar
• Steimle, V., L. A. Otten, M. Zufferey, and J. Mach 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135–146.
   PubMed Web of Science ®Google Scholar
• Steimle, V., C. A. Siegrist, A. Mottet, B. Lisowska-Grospierre, and J. Mach 1994. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265:106–109.
   PubMed Web of Science ®Google Scholar
• Ting, J. P.-Y., and J. Baldwin 1993. Regulation of MHC gene expression. Curr. Opin. Immunol. 5:8–16.
   PubMed Web of Science ®Google Scholar
• Ting, J. P.-Y., K. L. Wright, K.-C. Chin, W. J. Brickey, and J. Li 1997. The DMB promoter: delineation, in vivo footprint, trans-activation and transdominant-suppression. J. Immunol. 159:5457–5462.
   PubMedGoogle Scholar
• White, L. C., K. L. Wright, N. J. Felix, H. Ruffner, L. F. Reis, R. Pine, and J. Ting 1996. Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1−/− mice. Immunity 5:365–376.
   PubMedGoogle Scholar
• Wilson, I. A. 1996. Another twist to MHC-peptide recognition. Science 272:973–974.
   PubMedGoogle Scholar
• Mueller, P. R., and J. Wold 1989. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science 246:780–786.
   PubMed Web of Science ®Google Scholar
• Wright, K. L., K.-C. Chin, M. Linhoff, C. Skinner, J. A. Brown, J. M. Boss, G. R. Stark, and J. Ting 1998. CIITA stimulation of transcription factor binding to MHC class II and associated promoters in vivo. Proc. Natl. Acad. Sci. USA 95:6267–6272.
   PubMedGoogle Scholar
• Wright, K. L., and J. Ting 1992. In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma. Proc. Natl. Acad. Sci. USA 89:7601–7605.
   PubMedGoogle Scholar
• Zhou, S., L. Zawel, C. Lengauer, K. W. Kinzler, and J. Vogelstein 1998. Characterization of human FAST-1, a TGFβ and activin signal transducer. Mol. Cell 2:121–127.
   PubMed Web of Science ®Google Scholar